Skip to main content

Table 4 Estimates of costs in 2002 prices, health benefits and cost-effectiveness from Bolin et al. [10], assuming a five-year dwell time

From: Re-interpreting the data on the cost and effectiveness of population screening for colorectal cancer in Australia

Strategy Cost ($) Incremental changes in cost ($) Effectiveness (LYG) Incremental changes in effectiveness (LYG) Average cost-effectiveness ratio ($) Incremental cost-effectiveness ratio ($)
  (a) (b) (c) (d) (a)/(c) (b)/(d)
EXISTING PRACTICE 0   0   (Undefined)  
FOBT3 109,167,314 109,167,314 2,010 2,010 54,312 54,312
COL 195,987,062 86,819,748 1,166 -844 168,085 (Simply Dominated)
FSIG5 205,570,434 96,403,120 3,365 1,355 61,091 71,146
FOBT1 230,156,355 24,585,921 4,447 1,082 51,755 22,723
DCBE5 253,881,621 23,725,266 5,050 603 50,274 39,345
FSIG3 271,052,169 17,170,548 3,909 -1,141 69,341 (Simply Dominated)
COL10 278,701,522 24,819,901 3,718 -1,332 74,960 (Simply Dominated)
DCBE3 307,911,416 54,029,795 6,184 1,134 49,792 47,645
COL5 360,264,079 52,352,663 6,181 -3 58,286 (Simply Dominated)
FOBT1+FSIG5 364,595,167 56,683,751 5,849 -335 62,335 (Simply Dominated)
FOBT1+DCBE5 373,803,843 65,892,427 6,573 389 56,870 169,389
FOBT1+FSIG3 420,786,416 46,982,573 6,032 -541 69,759 (Simply Dominated)
FOBT1+DBCE3 424,911,339 51,107,496 7,020 447 60,529 114,334